Francesca Barone
Chief Tech/Sci/R&D Officer chez CANDEL THERAPEUTICS, INC.
Fortune : 294 918 $ au 31/03/2024
Profil
Francesca Barone is currently the Chief Scientific Officer at Candel Therapeutics, Inc. She previously worked as the Director-laboratories at the Institute of Translational Medicine.
From 2010 to 2019, she was an Associate Professor at the University of Birmingham.
In 2019, she became the Head-Experimental Medicine at Senda Biosciences, Inc. Dr. Barone holds a doctorate degree from Sapienza University of Rome and King's College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/11/2023 | 186 657 ( 0,65% ) | 294 918 $ | 31/03/2024 |
Postes actifs de Francesca Barone
| Sociétés | Poste | Début |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
Anciens postes connus de Francesca Barone
| Sociétés | Poste | Fin |
|---|---|---|
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/11/2020 |
| University of Birmingham | Corporate Officer/Principal | 01/05/2019 |
| Institute of Translational Medicine | Corporate Officer/Principal | - |
Formation de Francesca Barone
| Sapienza University of Rome | Doctorate Degree |
| King's College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
| Institute of Translational Medicine |
